PatentJun 22, 2026, 09:07 AM
Genprex Receives Canadian Patent for Reqorsa Gene Therapy in Lung Cancer
AI Summary
Genprex announced it received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa Gene Therapy in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This expands its intellectual property portfolio, which already includes patents in the U.S., Japan, Europe, and other countries. The patent strengthens protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. Lung cancer is a leading cause of death in Canada, with 32,900 diagnoses and 19,300 deaths estimated for 2026.
Key Highlights
- Canadian Intellectual Property Office issued a Notice of Allowance for a patent to Genprex.
- The patent covers Reqorsa Gene Therapy combined with PD-1 or PD-L1 antibodies.
- It applies to the treatment of non-small cell lung cancer and small cell lung cancer.
- This expands on previously granted patents in the U.S., Japan, Europe, and other countries.
- The patent strengthens intellectual property for therapeutic combinations in the Acclaim-3 clinical trial.
- Canadian Cancer Society estimates 32,900 lung cancer diagnoses in Canada in 2026.
- Canadian Cancer Society estimates 19,300 lung cancer deaths in Canada in 2026.
Price Impact
More from GNPX